Sleep Without Insomnia or The Use of Chronic Hypnotics
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- People taking part
- 188 people enrolled
- Started
- 11 Dec 2018
- Ended
- 27 Nov 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Program A
- Program B
- Record updated
- 7 April 2026
Who can take part
- Age
- 55 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Age >= 55 years
- Use of lorazepam, alprazolam, temazepam,and/or zolpidem for current or prior insomnia symptoms 2 or more nights per week for at least 3 months
- Current or prior insomnia symptoms
- Available to attend weekly in-person sessions over 9 weeks
Who cannot take part
- High baseline risk of complicated withdrawal;benzodiazepine intoxication or current or past symptoms of complicated benzodiazepine/alcohol withdrawal (e.g.,seizure, delirium at baseline (prior to taper))
- Unable to keep study medications in secure location
- Medically/psychiatrically unstable (e.g., planned major surgery during the study period;psychosis, suicidal, active alcohol/substance abuse based on history and medical records)
- Seizure disorder
- Evidence of prescription fraud (e.g., multiple prescriptions for same drug filled at multiple pharmacies during overlapping time periods, diversion); Discontinuation of hypnotic not appropriate:; •Study-targeted hypnotic used to treat another clinical condition (e.g., panic disorder); Poor candidate for cognitive behavioral therapy for insomnia:
- Presence of bipolar disorder
- Cognitive impairment (e.g., Mini-Mental State Examination < 24)
- Sleep/wake difficulty is better explained by another sleep disorder such as restless legs syndrome, narcolepsy, insufficient sleep syndrome, or circadian rhythm sleep-wake disorders
- High risk for complications in outpatient hypnotic discontinuation program:
- Supratherapeutic or high baseline hypnotic dose (> diazepam-equivalent of 8 mg/night)
- Polydrug use (e.g., chronic high dose opioids)
- Untreated sleep-disordered breathing (respiratory event index >= 15 and < 30 plus excessive daytime sleepiness, or REI >=30)
- Unstable housing situation
Where in United States
- University of California, Los AngelesLos Angeles, United States
- VA Greater Los AngelesLos Angeles, United States
About the trial
What the trial wants to find out
Sleeping medications, called hypnotics, are often prescribed for insomnia and are associated with adverse health outcomes in older adults. Response rates to hypnotic discontinuation programs are often inadequate, and many patients eventually resume use of hypnotics, suggesting that other mechanisms need to be targeted to achieve and sustain high rates of non-use. Current programs focus on the tapering of hypnotics and/or the treatment of insomnia symptoms. These programs employ strategies such as supervised gradual taper, cognitive behavioral therapy targeting hypnotic withdrawal, and/or cognitive behavioral therapy for insomnia. Evidence suggests that another mechanism involving "placebo" effects may be a viable target for achieving and sustaining higher discontinuation rates. Cognitive expectancies play a key role in producing placebo effects, which are characterized as real improvements in sleep arising from psychosocial aspects of treatment rather than drug effects alone. In this study, investigators are comparing two programs for discontinuing hypnotic medications-a program that addresses placebo effects associated with hypnotic use and a program that does not address these effects.
The 2 groups in the trial
- Program ATreatment being tested
cognitive behavioral therapy type A plus medications in packaging type A
- Program BExisting treatment, for comparison
cognitive behavioral therapy type B plus medications in packaging type B
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Novel Mechanism for Helping Older Adults Discontinue Use of Sleeping Pills
- Publications
- Sleep aid usage following benzodiazepine receptor agonist tapering and cognitive behavioral therapy for insomnia in middle-aged and older adults.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026
- Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial.JAMA internal medicine, 2024
- Record updated
- 7 April 2026